Porton Pharma plans to use its own funds of 30 million yuan to establish a new wholly owned subsidiary, Chongqing Yaochu Biotechnology Co., Ltd., to explore the health consumer goods business. The new subsidiary has a registered capital of 30 million yuan, with a business scope including the production of food additives and formula foods for special medical purposes. The company also disclosed its performance forecast for the first half of 2026, expecting operating revenue of 1.75 to 1.82 billion yuan, a year-on-year increase of 8% to 12%, but a net loss attributable to the parent company of 210 to 250 million yuan, mainly due to an asset impairment provision of approximately 330 million yuan for terminating the construction of a research and development and production base in Slovenia. Excluding the impact of this impairment, the net profit attributable to the parent company for the first half is expected to be 80 to 120 million yuan, a year-on-year increase of 196% to 343%.
Porton Fine Chemicals LtdPlans to establish a subsidiary for health consumer goods business and reports strong core profit growth (196-343% ex-impairment).